November 25, 2016 - By Marguerite Chambers · 0 Comments
The stock of Bio Path Holdings DE (NASDAQ:BPTH) registered an increase of 4.62% in short interest. BPTH’s total short interest was 2.37M shares in November as published by FINRA. Its up 4.62% from 2.27M shares, reported previously. With 84,600 shares average volume, it will take short sellers 28 days to cover their BPTH’s short positions. The short interest to Bio Path Holdings DE’s float is 2.75%. The stock increased 3.15% or $0.04 during the last trading session, hitting $1.31. About 35,341 shares traded hands. Bio-Path Holdings Inc (NASDAQ:BPTH) has declined 53.65% since April 22, 2016 and is downtrending. It has underperformed by 59.06% the S&P500.
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The company has a market cap of $125.30 million. The Firm utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. It currently has negative earnings. The Company’s drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.
Insitutional Activity: The institutional sentiment decreased to 1.92 in Q2 2016. Its down 0.75, from 2.67 in 2016Q1. The ratio dropped, as 11 funds sold all Bio-Path Holdings Inc shares owned while 4 reduced positions. 23 funds bought stakes while 17 increased positions. They now own 19.60 million shares or 75.34% more from 11.18 million shares in 2016Q1.
State Common Retirement Fund last reported 0% of its portfolio in the stock. Rhumbline Advisers accumulated 70,240 shares or 0% of the stock. Geode Cap Mgmt Ltd Co reported 618,109 shares or 0% of all its holdings. The Minnesota-based Walleye Trading Lc has invested 0% in Bio-Path Holdings Inc (NASDAQ:BPTH). Financial Bank Of America Corp De last reported 1,567 shares in the company. Proshare Advsr Ltd Llc last reported 0% of its portfolio in the stock. Bankshares Of Mellon Corp holds 0% or 283,747 shares in its portfolio. Moreover, California State Teachers Retirement Sys has 0% invested in Bio-Path Holdings Inc (NASDAQ:BPTH) for 174,138 shares. Tiaa Cref Management Ltd Limited Liability Company last reported 0% of its portfolio in the stock. Legal General Public Limited Liability Company accumulated 0% or 15,229 shares. Gsa Capital Partners Llp last reported 17,300 shares in the company. Bnp Paribas Arbitrage Sa holds 3,284 shares or 0% of its portfolio. The New York-based Blackrock has invested 0% in Bio-Path Holdings Inc (NASDAQ:BPTH). Principal Group Incorporated has 14,613 shares for 0% of their US portfolio. Voya Invest Lc reported 44,232 shares or 0% of all its holdings.
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Firm utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. The Company’s drug delivery and antisense technology, called DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a neutral charged lipid bilayer. In vivo, the DNAbilize delivered antisense drug substances are systemically distributed across the body to allow for reduction or elimination of proteins in blood diseases and solid organs. Using DNAbilize as a platform for drug manufacturing, the Company has approximately two antisense drug candidates in development to treat a total of over five different disease indications.
More news for Bio-Path Holdings Inc (NASDAQ:BPTH) were recently published by: Quotes.Wsj.com, which released: “News Bio-Path Holdings Inc.BPTH” on April 03, 2011. Seekingalpha.com‘s article titled: “Bio-Path Holdings, Inc. (BPTH) CEO Peter Nielsen on Q2 2016 Results – Earnings …” and published on August 10, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Marguerite Chambers